Market news

Century Therapeutics' CNTY-813 aims to deliver insulin-producing islets without chronic systemic immunosuppression. Find out why IPSC stock is a buy.

Detailed price information for Century Therapeutics Inc (IPSC-Q) from The Globe and Mail including charting and trades.

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the appointment of Joseph Truitt to its Board of Directors. Truitt currently serves as Chief Executive Officer and a member of the Board of Directors of iECURE, Inc., a clinical-stage biotechnology company advancing

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1DUpcoming oral presentations at European Association for the Study of Diabetes (EASD 2026) and Break

Century Therapeutics, Inc. (NASDAQ:IPSC) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses. Both presentations will highlight CNTY-813, Century’s iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients […]

PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2